The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy

There are many treatments for metastatic colorectal cancer (mCRC). Among them, uncertainty remains especially concerning the clinical benefit of different regimens for left-sided RAS wild-type (WT) mCRC in the triple-drug therapy era. No studies have been conducted to answer this critical clinical i...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Changjing, Luo, Qingqing, Liu, Yihan, Peng, Yinghui, Zhang, Xiangyang, Jiang, Zhaohui, Feng, Ziyang, Qi, Yaru, Gao, Yan, Liu, Yongting, Liu, Ping, Chen, Yihong, Guo, Cao, Shen, Hong, Zeng, Shan, Han, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561342/
https://www.ncbi.nlm.nih.gov/pubmed/36249804
http://dx.doi.org/10.3389/fphar.2022.1015510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561342/
https://www.ncbi.nlm.nih.gov/pubmed/36249804
http://dx.doi.org/10.3389/fphar.2022.1015510

Ejemplares similares